



ZELTIQ® Announces Filing of S-1 Registration Statement

PLEASANTON, Calif. (JULY 13, 2011) -- ZELTIQ Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers and William Blair & Company, L.L.C. and Canaccord Genuity Inc. are acting as co-managers of the proposed offering.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204; or Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, by calling toll-free (866) 471-2526, by facsimile (212) 902-9316 or by emailing prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About ZELTIQ Aesthetics, Inc.

We are a medical technology company focused on developing and commercializing products utilizing our proprietary controlled-cooling technology platform. Our first commercial product, the CoolSculpting® System, selectively reduces stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is clinically proven to reduce fat bulges in a 60-minute procedure, allowing patients to achieve noticeable and measurable aesthetic results. We have received regulatory clearance from the U.S. Food and Drug Administration to market CoolSculpting in the United States for the selective reduction of fat around the flanks. We also have received regulatory approval or are otherwise free to market CoolSculpting in 46 international markets.

###

MEDIA CONTACT:

Shari Gold
GOLD PR for ZELTIQ
714-251-0375
sgold@goldpr.com